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Hybrid derivative of cathelicidin 
and human beta defensin‑2 
against Gram‑positive bacteria: 
A novel approach for the treatment 
of bacterial keratitis
Darren Shu Jeng Ting1,2,3, Eunice Tze Leng Goh3, Venkatesh Mayandi3, Joanna M. F. Busoy3, 
Thet Tun Aung3, Mercy Halleluyah Periayah3, Mario Nubile4, Leonardo Mastropasqua4, 
Dalia G. Said1,2, Hla M. Htoon3, Veluchamy Amutha Barathi3, Roger W. Beuerman3,5, 
Rajamani Lakshminarayanan3, Imran Mohammed1,6 & Harminder S. Dua1,2,6*
Bacterial keratitis (BK) is a major cause of corneal blindness globally. This study aimed to develop a 
novel class of antimicrobial therapy, based on human‑derived hybrid host defense peptides (HyHDPs), 
for treating BK. HyHDPs were rationally designed through combination of functional amino 
acids in parent HDPs, including LL‑37 and human beta‑defensin (HBD)‑1 to ‑3. Minimal inhibitory 
concentrations (MICs) and time‑kill kinetics assay were performed to determine the concentration‑ 
and time‑dependent antimicrobial activity and cytotoxicity was evaluated against human corneal 
epithelial cells and erythrocytes. In vivo safety and efficacy of the most promising peptide was 
examined in the corneal wound healing and Staphylococcus aureus (ATCC SA29213) keratitis murine 
models, respectively. A second‑generation HyHDP (CaD23), based on rational hybridization of the 
middle residues of LL‑37 and C‑terminal of HBD‑2, was developed and was shown to demonstrate 
good efficacy against methicillin‑sensitive and methicillin‑resistant S. aureus [MIC = 12.5–25.0 μg/
ml (5.2–10.4 μM)] and S. epidermidis [MIC = 12.5 μg/ml (5.2 μM)], and moderate efficacy against P. 
aeruginosa [MIC = 25‑50 μg/ml (10.4–20.8 μM)]. CaD23 (at 25 μg/ml or 2× MIC) killed all the bacteria 
within 30 min, which was 8 times faster than amikacin (25 μg/ml or 20× MIC). After 10 consecutive 
passages, S. aureus (ATCC SA29213) did not develop any antimicrobial resistance (AMR) against CaD23 
whereas it developed significant AMR (i.e. a 32‑fold increase in MIC) against amikacin, a commonly 
used treatment for BK. Pre‑clinical murine studies showed that CaD23 (0.5 mg/ml) achieved a median 
reduction of S. aureus bioburden by 94% (or 1.2  log10 CFU/ml) while not impeding corneal epithelial 
wound healing. In conclusion, rational hybridization of human‑derived HDPs has led to generation of 
a potentially efficacious and safe topical antimicrobial agent for treating Gram‑positive BK, with no/
minimal risk of developing AMR.
Infectious keratitis (IK) represents a major cause of corneal blindness worldwide, with an incidence ranging 
from 2.5 to 799 per 100,000 population-year1,2. It is a common, yet potentially sight-threatening, ophthalmic 
emergency that often warrants hospital admission for intensive antibiotic treatment and monitoring. IK can be 
caused by a wide array of microorganisms, including bacteria, fungi, protozoa and viruses. Among all, bacterial 
keratitis (BK) has been shown to be the main cause for IK in many developed countries, including the US and the 
UK (> 90% cases), with Staphylococci spp. (30–60%) and Pseudomonas aeruginosa (10–25%) being the two most 
common bacteria  reported1,3–7. In view of the diverse causative microorganisms, intensive broad-spectrum topical 
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antibiotics are often administered during the initial treatment of IK. In refractory cases of IK, adjuvant therapy 
such as photoactivated chromophore-corneal cross-linking (PACK-CXL), amniotic membrane transplant, and 
therapeutic keratoplasty, are often  warranted8–11.
The current management of IK is challenged by several factors, including the low culture  yield1,2, polymi-
crobial  infection12,13, and emerging trend of antimicrobial resistance (AMR)1,14,15. In the Antibiotic Resistance 
Monitoring in Ocular Microorganisms (ARMOR) 10-year prospective study, it was shown that 35–50% of the 
Staphylococci spp. were methicillin-resistant, with ~ 75% of them being multidrug resistant (i.e. resistant to ≥ 3 
antibiotic classes)5. More compellingly, the increased level of AMR of the causative microorganism has been 
shown to negatively influence the corneal healing time and final visual  outcome16,17. Furthermore, complications 
such as corneal melt, perforation and endophthalmitis may ensue despite timely and intensive antibiotic treat-
ment, necessitating eye-saving surgeries such as tectonic  keratoplasty11,18,19. All these issues highlight an unmet 
need for new antimicrobial treatment for IK, particularly that no new class of antibiotic has been discovered 
since  198720.
Host defense peptides (HDPs), or previously known as antimicrobial peptides (AMPs), play vital roles in the 
innate immune  system21,22. They are a group of evolutionary conserved small molecules that are ubiquitously 
expressed by the immune cells and the front-line defense structures, including the ocular surface (OS)23,24. 
They have recently shown promise as potential therapeutic agents due to their broad-spectrum antimicrobial 
properties with minimal risk of developing  AMR25. These molecules are usually highly cationic and amphiphilic, 
with 30–50% of hydrophobicity. The cationic amino acid residues (i.e. lysine and arginine) facilitate the binding 
of HDPs onto the anionic bacterial membrane (via electrostatic interaction), while the hydrophobic residues 
interact with the lipid tail region of the membrane, culminating in membrane disruption, leakage of cytoplasmic 
contents and subsequent cell  death26.
Previous studies have demonstrated that numerous HDPs, including LL-37, human beta-defensin (HBD)-2 
and -3, are expressed at the OS and upregulated during  IK23,27–31. HBD-9, on the other hand, was shown to be 
downregulated during  IK32. In addition, it was demonstrated that the modulated levels of HBD-3 and HBD-9 on 
OS during BK returned to normal baseline following complete healing of  ulcers33. Furthermore, HDPs exhibit 
moderate in vitro antimicrobial activity [minimum inhibitory concentration (MIC) of around 50–100 μg/mL) 
against common ocular surface pathogenic isolates such as S. aureus and P. aeruginosa34,35, highlighting their 
essential functions in human OS defense.
Despite their promising potential as effective antimicrobial therapies, several issues have impeded the success-
ful translation of HDPs to clinical use. These include their complex structure–activity relationship (SAR), sus-
ceptibility to host/bacterial proteases, physiological conditions, and toxicity to host tissues, amongst  others25,36,37. 
In view of these issues, a number of novel strategies, including residue substitution, chemical modification, and 
hybridization, have been proposed to enhance the therapeutic potential of  HDPs25,36,37.
A number of hybrid peptides, including cecropin A-melittin38, cecropin A-LL3739, melittin-protamine40,41, 
amongst  others25, have been previously designed and reported in the literature. When compared to the parent 
peptide, these hybrid peptides demonstrated improved antimicrobial efficacy and/or reduced toxicity to host 
tissues. However, strategies in combining two human-derived HDPs from two different classes (e.g. LL-37 and 
HBD) have not been previously explored. In this study, we aimed to develop novel topical antimicrobial treat-
ment for BK using hybridized HDPs derived from different combination of LL-37 and HBD-1 to -3, which are 
all important HDPs expressed at the OS. The in vivo efficacy and safety of the most promising molecule, CaD23 
(a hybrid derivative of LL-37 and HBD-2), was further examined and validated in murine corneal wound heal-
ing and S. aureus keratitis models.
Results
In vitro antimicrobial efficacy of HDPs. A total of 12 synthetic HDPs were rationally designed and 
synthesized based on the templates of native LL-37 and HBD-1 to -3 (Table 1). The MIC values (in μg/ml and 
μM) of all the tested antibiotics, single and hybrid peptides, in the absence and presence of 150 mM NaCl are 
summarized in Table 2.
For reference and comparison purposes, the antimicrobial efficacy of the full-length sequence of LL-37 and 
HBD2 and HBD3 was first determined, though extensive examination was not performed in view of the lack of 
translational potential for clinical use (due to the cost of synthesis associated with long length of the peptides). 
LL-37 demonstrated moderate-to-good efficacy against methicillin-sensitive S. aureus [MSSA; MIC = 25.0 μg/
ml], methicillin-resistant S. aureus [MRSA; MIC = 25 μg/ml] and P. aeruginosa PAO1-L (MIC = 50 μg/ml) whereas 
HBD2 and HBD3 exhibited low efficacy (MIC = 100 μg/ml) against all three organisms. Subsequently, the effi-
cacy of the three truncated versions of peptides (6–12 amino acids; based on the native template of HBD-2, 
HBD-3 and LL-37) and 6 first-generation hybrid HDPs (based on different combinations of LL-37, and HBD-1 
to -3) were examined. All of them did not demonstrate any significant antimicrobial efficacy (MIC ≥ 200 μg/ml) 
against either Gram-positive or Gram-negative bacteria. Further 3s-generation peptides (derived from CaD2 
sequence) were synthesized through rational modification: (1) CaD21: substitution of cysteine with alanine; (2) 
CaD22: substitution of phenylalanine with tryptophan (to increase hydrophobicity); and (3) CaD23: substitu-
tion of phenylalanine and proline with tryptophan (to further enhance hydrophobicity) and substitution of 
cysteine with leucine. CaD21 and CaD22 demonstrated slight improvement in the antimicrobial efficacy whereas 
CaD23 exhibited good antimicrobial efficacy against MSSA (MIC = 12.5–25.0 μg/ml), (MRSA; MIC = 25 μg/ml) 
and methicillin-sensitive Staphylococcus epidermidis [MSSE; MIC = 12.5 μg/ml], highlighting the importance of 
increased hydrophobicity for antimicrobial efficacy (Table 1). Moderate efficacy of CaD23 was observed against 
P. aeruginosa (MIC = 25–50 μg/ml). When tested in the presence of physiological tear salt concentration (150 mM 
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NaCl), the MIC of CaD23 against MSSA and MRSA increased by two to fourfold, remained unchanged for MSSE, 
and remained relatively stable (one to twofold increase) against P aeruginosa.
In vitro cell viability and cytotoxicity. Amikacin and CaD2 did not demonstrate any lethal effect on 
HCE-2 cell viability at 200 μg/ml (Fig. 1A). The  IC50 (concentration that inhibits 50% of the cell viability) of 
CaD21, CaD22 and CaD23 were > 200 μg/ml, > 200 μg/ml and 54.6 ± 11.7 μg/ml, respectively. This demonstrated 
that the increased hydrophobicity with tryptophan residues enhanced the antimicrobial efficacy of CaD23 but 
with increased negative effect on the cell viability of HCE-2 cells. In terms of cytotoxicity, amikacin and CaD2 
did not show any sign of toxicity for HCE-2 cells at 200 μg/ml and CaD23 showed 30.4 ± 7.8% cytotoxicity at 
200 μg/ml (Fig. 1B). The  LC50 (concentration that kills 50% of the cells) of CaD23 was > 200 μg/ml, which yielded 
a therapeutic index (defined by  LC50 divided by the MIC value) of > 8 for treating S. aureus ATCC29213. Hemo-
lytic assay demonstrated minimal (7.1 ± 3.0%) hemolytic activity of CaD23 at 200 μg/ml (Fig. 2). A summary of 
the cell viability, cytotoxicity and hemolytic results of CaD23 is provided in Table 3. In addition, a summary of 
the therapeutic index of CaD23 (defined as  IC50,  LC50 or  HC50 divided by the MIC value) is provided in Table 4.
Time‑kill kinetics. Time- and concentration-dependent antimicrobial activity of CaD23 was determined 
against MSSA (SH1000) using time-kill kinetics assay. When CaD23 was used at 2× MIC (25 μg/ml) against 
SH1000, it was able to achieve significant killing (99.9% or 3  log10 CFU/ml reduction) with 15 min and complete 
killing (100%) within 30 min of treatment (Fig. 3). In contrast, amikacin (used at 20× MIC; 25 μg/ml) could only 
achieve significant and/or complete killing (99.9–100%) of SH1000 within 4 h of treatment, which was 8 times 
slower than CaD23. The antimicrobial efficacy of CaD23 (25 μg/ml) and amikacin (both 10 μg/ml and 25 μg/ml) 
were maintained at 24 h’ time-point, with no evidence of bacterial re-growth. Similar findings were observed 
when CaD23 and amikacin were tested against SH1000 in physiological tear salt concentration (150 mM NaCl). 
Table 1.  Summary of the native and synthetic host defense peptide (HDP) sequences. Calculation of 
the physicochemical properties of the peptides was performed using PepCalc (https:// pepca lc. com/) and 
HeliQuest (https:// heliq uest. ipmc. cnrs. fr/ cgi- bin/ Compu tPara ms. py). HBD: human beta-defensin; AA: amino 
acids; HyHDPs: hybrid host defense peptides; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; 
G: glycine; I: isoleucine; K: lysine; L: leucine; N: aspargine; P: proline; Q: glutamine; R: arginine; S: serine; 
T: theorine; V: valine; W: tryptophan. a The sequence is too short for calculation of hydrophobicity and 
hydrophobic moment.













41 4334.2  + 6 0.489 0.246
HBD3
GIINTLQKYY CRVRGG 
RCA V LSCLPKEEQI 
GKCSTRGRKC CRRKK





37 4493.3  + 6 0.201 0.521
Synthetic single HDPs
Ca12 KRIVQRIKDF LR 12 1571.9  + 4 0.193 0.782
BD2a KCCKKP 6 705.9  + 3 – –
BD3 RGRKCCRRKK 10 1290.6  + 7 − 0.393 0.300
1st generation HyHDPs
DD12 RGKAKCCKGT KCCKKP 16 1739.2  + 7 0.031 0.144
DD13 RGKAKCCKRG RKC-CRRKK 18 2165.7  + 11 − 0.251 0.200
DD32 RGRKCCRRKK KCCKKP 16 1978.5  + 10 − 0.194 0.201
CaD1 KRIVQRIKDF LRRG-KAK 17 2112.6  + 7 − 0.022 0.383
CaD2 KRIVQRIKDF LRKC-CKKP 18 2259.8  + 7 0.174 0.445
CaD3 RIKDFLRNGR KCCRRKK 17 2177.7  + 8 − 0.118 0.234
2nd generation HyHDPs
CaD21 KRIVQRIKDF LRKACKKP 18 2227.8  + 7 0.106 0.443
CaD22 KRIVQRIKDW LRKC-CKKP 18 2298.9  + 7 0.200 0.456
CaD23 KRIVQRIKDW LRKL-CKKW 18 2398.0  + 7 0.294 0.456
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CaD23 (100 μg/ml; 4× MIC) was able to achieve complete killing of S. aureus within 15 min of treatment whereas 
amikacin (20 μg/ml; 8× MIC) was only able to achieve complete killing within 4 h of treatment (Fig. 4).
Multipassage antimicrobial resistance (AMR) study. Multipassage AMR assays were performed to 
evaluate the risk of development of AMR of S. aureus ATCC SA29213 against CaD23 and amikacin over 10 
consecutive passages (days). S. aureus did not develop any AMR against CaD23 after 10 consecutive passages 
whereas it developed significant AMR against amikacin, with a fourfold increase in the MIC after the 2nd pas-
sage and a 32-fold increase in the MIC after the 10th passage (Fig. 5). This highlights the therapeutic potential of 
CaD23 as novel antimicrobial agent in the era of emerging AMR.
In vivo safety of CaD23. In view of the known discrepancy between in vitro and in vivo results, the safety 
of CaD23 was further determined in a murine corneal epithelial wound healing model. When compared to 
the PBS group, both CaD23 0.03% (or 300 μg/ml) and CaD23 0.05% (or 500 μg/ml) groups did not show any 
significant difference in the rate of corneal re-epithelialization (all healed within 2–3 days), suggesting that both 
concentrations were safe for topical application (Fig. 6). However, significant delay in corneal re-epithelialization 
was observed in the CaD23 0.1% group, with a mean wound size of 28.5 ± 19.9% at day 3 post-injury (p = 0.004).
In vivo efficacy of CaD23. Based on the in vivo safety results, the highest tolerable concentration of CaD23 
0.05% was subjected to subsequent in vivo efficacy testing in a murine S. aureus ATCC 29213 keratitis model. 
As the data was not normally distributed and was log-transformed, the results were reported in median ± inter-
Table 2.  A summary of the minimum inhibitory concentrations (MICs) of various antibiotics and synthetic 
human-derived hybrid host defense peptides. All experiments were performed in full-strength cationic Muller-
Hinton broth (i.e. MHB-2) and in the absence or presence of physiological tear salt concentration (150 mM 
NaCl). The MIC values are presented in μg/ml (and μM in bracket). When the MIC level was ≥ 200 μg/ml in 
the absence of salt, the peptide was not subjected to testing in the presence of salt. MIC refers to the lowest 
concentration of antibiotic/peptide that prevents any visible bacterial growth after 24 h of incubation with 
treatment. Data represent the mean of two biological duplicate from two to three independent experiments. 
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PAO1-L P. aeruginosa PA-OS
0 mM 150 mM 0 mM 150 mM 0 mM 150 mM 0 mM 150 mM 0 mM 150 mM 0 mM 150 mM 0 mM 150 mM
Antibiot-
ics






























LL37 25 (5.6) – – – 25 (5.6) – – – – – 50 (11.1) – – –
HBD2 100 (23.1) – – –
100 
(23.1) – – – – –
100 
(23.1) – – –
HBD3 100 (19.4) – – –
100 
(19.4) – – – – –
100 




Ca12  > 200 (> 127.2) – – –
 > 200 
(> 127.2) – – – – –
200 
(127.2) – – –
BD2-6  > 200 (> 283.3) – – –
 > 200 
(> 283.3) – – – – –
 > 200 
(> 283.3) – – –
BD3-10  > 200 (> 154.9)
 > 200 
(> 154.9)
 > 200 





DD12  > 200 (> 115) – – –
 > 200 
(> 115) – – – – –
 > 200 
(> 115) – – –
DD13  > 200 (> 92.3) – – –
 > 200 
(> 92.3) – – – – –
 > 200 
(> 92.3) – – –
DD32  > 200 (> 101) – – –
 > 200 
(> 101) – – – – –
 > 200 
(> 101) – – –
CaD1  > 200 (> 94.7) – – –
 > 200 
(> 94.7) – – – – –
 > 200 
(> 94.7) – – –
CaD2  > 200 (> 88.5) – – –
 > 200 
(> 88.5) – – – – –
 > 200 
(> 88.5) – – –
CaD3  > 200 (> 91.8) – – –
 > 200 
(> 91.8) – – – – –
 > 200 






CaD21 200 (89.8) – – –
 > 200 








 > 200 
(> 87.0) – –
 > 200 











(5.2) 50 (20.8) 50 (20.8) 25 (10.4) 50 (20.8)
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quartile range (IQR). When compared to the S. aureus bacterial viability in the PBS group (4.2 ± 1.3  log10 CFU/
ml), there was a considerable reduction of bacterial viability in the CaD23 0.05% and levofloxacin 0.5% groups 
by 94% (3.0 ± 2.4  log10 CFU/ml; p = 0.72) and 98% (2.4 ± 2.2  log10 CFU/ml; p = 0.08), respectively, though statisti-
cal significance was not achieved due to wide standard deviations (Fig. 7). At day 3 post-treatment, the clinical 
appearance of the corneas in the CaD23-treated group (1.2 ± 0.45; p = 0.07) and the levofloxacin-treated group 
(1.0 ± 0.71; p = 0.03) was substantially better than the untreated group (2.2 ± 0.84), based on the ocular clinical 
scoring (Fig. 7).
Discussion
IK represents a persistent and uncurbed burden on human health at a global level. Topical antibiotics are the cur-
rent mainstay of treatment for BK but the efficacy is being increasingly challenged by the emergence of  AMR1,2,14. 
In addition, patients with BK often require long duration of treatment and sight-threatening complications may 
still ensue despite timely  intervention11, highlighting an unmet need for newer and better treatment. HDPs serve 
as an attractive class of antibiotics for treating IK based on the following reasons: (1) the broad-spectrum activ-
ity of HDPs can provide comprehensive coverage to a wide range of microorganisms, particularly when mixed 
infection is relatively common (5–20%) in  IK1; (2) the rapid antimicrobial action help reduce the microbial load 
and limit the damage to the cornea more effectively, ultimately have a better chance of preserving the vision, 
as well as reducing the risk of developing AMR, which is currently an emerging issue in ocular  infection14; and 
Figure 1.  Cytotoxicity of synthetic peptides and amikacin (a commonly used antibiotic for bacterial keratitis) 
in various concentrations against human corneal epithelial cells (HCE-2), presented as dose–response 
curves (normalized, variable slope). Percentage cell viability is presented as mean ± standard deviation 
(depicted in error bars) of two independent experiments performed in biological duplicate. Some error bars 
are missing due to small standard deviation values. (A) Cell viability assay (using cell counting kit-8 assay) 
demonstrating normal metabolic activity of epithelial cells in CaD2 and amikacin but reduced activity in CaD23 
 (IC50 = 54.6 ± 11.7 μg/ml) after 3 h of treatment.  IC50 (concentration of treatment inhibiting 50% of cell viability) 
is shown in a black dotted line. (B) Cytotoxicity assay (using lactate dehydrogenase assay) demonstrating no 
sign of cytotoxicity of epithelial cells in amikacin and CaD2, and low level of cytotoxicity in CaD23 (30.4 ± 7.8% 
at 200 μg/ml;  LC50 > 200 μg/ml) after 3 h of treatment.
Figure 2.  Hemolytic effect of CaD23 and levofloxacin (a commonly used antibiotic for bacterial keratitis) 
in various concentrations against fresh human erythrocytes, determined after 1 h of treatment. Percentage 
hemolysis is presented as mean ± standard deviation (depicted in error bars) of two independent experiments 
performed in biological duplicate. Some error bars are missing due to small standard deviation values. The 
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Table 3.  Summary of the cytotoxicity, cell viability and hemolytic results of antibiotics and synthetic peptides 
(in µg/ml concentration). The cytotoxicity and cell viability results were obtained after 3 h of treatment whereas 
hemolytic effect of treatment was examined after 1 h of treatment. Results are presented in mean (SD) of two 
independent experiments performed in biological duplicate. Toxicity results of some peptides were missing 
because their antimicrobial efficacy was poor and hence toxicity was not determined. LC50: concentration of 
treatment causing 50% cytotoxicity;  Lmax (%): percentage of cytotoxicity at 200 µg/ml treatment concentration; 
 IC50: concentration of treatment causing 50% inhibition of cell viability;  Imax (%): percentage of inhibition of 
cell viability at 200 µg/ml treatment concentration;  HC50: concentration of treatment causing 50% hemolysis; 
 Hmax (%): percentage of hemolysis at 200 µg/ml treatment concentration.
Types Agents LC50 Lmax (%) IC50 Imax (%) HC50 Hmax (%)
Antibiotics
Amikacin  > 200 0.0 (0.1)  > 200 100.1 (7.3)  > 200 0.0
Levofloxacin  > 200 1.2 (0.7)  > 200 108.0 (2.8)  > 200 0 (0.0)
First-generation peptides
DD12 – – – – – –
DD13 – – – – – –
DD32 – – – – – –
CaD1 – – – – – –
CaD2  > 200 2.9 (2.2)  > 200 1.9 (7.3) – –
CaD3 – – – – – –
Second-generation peptides
CaD21 – –  > 200 43.9 (1.0) – –
CaD22 – –  > 200 34.3 (8.2) – –
CaD23  > 200 26.6 (6.5) 54.6 (11.7) 69.6 (7.8)  > 200 7.1 (3.0)
Table 4.  Summary of therapeutic index of CaD23 determined based on cytotoxicity, cell viability, and 
hemolytic results. The minimum inhibitory concentration (MIC) values, based on the results in the presence 
of full-strength cationic Muller-Hinton broth (caMHB) without salt, and therapeutic index (TI) values are 
presented in mean values. MRSA: methicillin-resistant Staphylococcus aureus; OS: ocular surface (clinical 
isolate);  LC50: concentration of treatment causing 50% cytotoxicity;  IC50: concentration of treatment causing 

















MIC TI MIC TI MIC TI MIC TI MIC TI MIC TI MIC TI
Based on  LC50 (= > 200) 12.5  > 16 25  > 8 25  > 8 50  > 4 12.5  > 16 50  > 4 25  > 8
Based on  IC50
(= 55) 12.5 4.4 25 2.2 25 2.2 50 1.1 12.5 4.4 50 1.1 25 2.2
Based on  HC50 (= > 200) 12.5  > 16 25  > 8 25  > 8 50  > 4 12.5  > 16 50  > 4 25  > 8
Figure 3.  Time-kill kinetics of CaD23 (0.25× MIC and 2× MIC) amikacin (8× and 20× MIC) against S. aureus 
(SH1000) in cation-adjusted Muller-Hinton broth over 24 h. Phosphate buffer solution (PBS) group serves 
as the untreated control. “0 min” represents the starting inoculum, which is around 6  log10 CFU/ml. The red 
dotted horizontal line at 3  log10 CFU/ml signifies the threshold of significant bacterial killing (defined as 99.9% 
or 3  log10 CFU/ml reduction of the bacterial viability compared to the starting inoculum). Data is presented as 
mean ± standard deviation (depicted in error bars) of two independent experiments performed in biological 
duplicate. CaD23 (2× MIC) was able to achieve complete (100%) killing of SH1000 within 30 min of treatment 
whereas amikacin (8× MIC and 25× MIC) was only able to achieve complete killing of SH1000 within 4 h of 
treatment. The antimicrobial efficacy of CaD23 and amikacin was maintained at 24 h post-treatment.
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(3) HDPs can be used as synergistic or additive agents to the current conventional antibiotics, enhancing the 
therapeutic index by increasing the antimicrobial efficacy and reducing the dose-related  toxicity42,43.
In this study, we highlight a body of work in designing and developing human-derived hybrid HDP as topical 
treatment for BK. Hybridization strategy has been previously employed by several research groups to improve 
the therapeutic index of  HDPs39,40,44 but the strategy of using human-derived hybrid HDPs (with LL-37 and 
HBD-2) is first of its kind. The initial concept of developing synthetic HDPs derived from LL-37 and HBD 
was founded on the observation of the upregulation of these key HDPs at the ocular surface during  IK23,27,33,45. 
Furthermore, LL-37 and HBD-2 and -3 were shown to exhibit good antimicrobial efficacy against a range of 
 organisms34,45. We have selected the mid-region of LL-37, consisting of residues 18–29 of LL-37 (i.e. KR-12) as 
part of the hybrid template as studies have demonstrated that KR-12, though much shorter than parent LL-37, 
exhibited similar antimicrobial activity against E. coli (MIC =  ~ 64 μg/ml) with reduced toxicity to host  cells46. 
C-terminal of HBD1-3 was used as the other part of the hybrid template in view of its rich content of cationic 
residues, which have been shown to play an important role in interacting with anionic bacterial membrane and 
killing of  bacteria47,48.
Our initial attempt of engineering single linear HDPs (including LL-37 and HBD-2 and -3) and hybrid HDPs 
(based on LL-37 and HBD-1 to -3) did not yield any compound with good antimicrobial efficacy. However, with 
systematic SAR analysis and modification, particularly through substitution of proline and phenylalanine with 
tryptophan residues (to increase hydrophobicity and membrane partitioning), ensued the development of peptide 
with enhanced antimicrobial efficacy against MSSA (MIC = 12.5–25 μg/ml) and MRSA (MIC = 25 μg/ml), serv-
ing as a proof-of-concept of this novel design strategy. Interestingly, increased hydrophobicity augmented the 
Figure 4.  Time-kill kinetics of CaD23 (4× MIC) and amikacin (8× MIC) against S. aureus (SH1000) in cation-
adjusted Muller-Hinton broth and physiological tear salt concentration (150 mM NaCl) over 24 h. Phosphate 
buffer solution (PBS) group serves as the untreated control. “0 min” represents the starting inoculum, which is 
around 6  log10 CFU/ml. The red dotted horizontal line at ~ 3  log10 CFU/ml signifies the threshold of significant 
bacterial killing (defined as 99.9% or 3  log10 CFU/ml reduction of the bacterial viability compared to the 
starting inoculum). Data is presented as mean ± standard deviation (depicted in error bars) of two independent 
experiments performed in biological duplicate. CaD23 (4× MIC) was able to achieve complete (100%) killing 
of SH1000 within 15 min of treatment whereas amikacin (8× MIC) was only able to achieve complete killing 
of SH1000 within 4 h of treatment. The antimicrobial efficacy of CaD23 and amikacin was maintained at 24 h 
post-treatment.
Figure 5.  Multipassage antimicrobial resistance (AMR) assays for CaD23 and amikacin against S. aureus 
ATCC SA29213 over 10 consecutive passages (days). S. aureus did not develop any AMR against CaD23 after 
10 passages whereas it developed significant AMR against amikacin, with a fourfold increase in the MIC after 
the 2nd passage and a 32-fold increase in the MIC after the 10th passage. Data is presented as mean ± standard 
deviation (depicted in error bars) of two independent experiments performed in biological duplicate. Some 
error bars are missing due to small or no standard deviation values.
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antimicrobial activity of HDP against Gram-positive bacteria more than Gram-negative bacteria. This is likely 
attributed to the different compositions in the bacterial membrane between Gram-positive bacteria, which consist 
of a thick peptidoglycan layer, and Gram-negative bacteria, which comprises an additional outer membrane with 
abundance of negatively charged lipopolysaccharide for which cationicity of the peptide plays a more important 
 role49. In addition, the efficacy of CaD23 (18 amino acids in length) is at least equal to or stronger than the full-
length parent LL37 (MIC = 25–50 μg/ml), HBD-2 (MIC = 100 μg/ml) and HBD-3 peptides (MIC = 50–100 μg/
ml). Peptides with shorter sequence not only have the advantage of lower manufacturing cost but may also have 
Figure 6.  In vivo safety of CaD23 in various concentrations [0.03% (or 300 μg/ml), 0.05% (or 500 μg/ml), and 
0.1% (1 mg/ml)] and phosphate buffer solution (PBS) assessed in a murine corneal epithelial wound healing 
model (n = 4 mice/treatment group). (A) Representative slit-lamp images showing the daily progress of corneal 
wound healing of each treatment group. The green color-stained area depicts the corneal epithelial defect. 
Complete corneal re-epithelialization was observed in all treatment groups, except CaD23 0.1% group, by day 
3. The images were analyzed using ImageJ software (https:// imagej. nih. gov/ ij/)67. (B) Graphical summary of 
the progress of corneal re-epithelialization of each treatment group over 3 days. The corneal epithelial wound 
size at various time points is calculated based on the original 100% wound size at baseline. Data is presented as 
mean ± standard deviation.
Figure 7.  In vivo efficacy of CaD23 0.05% (500 μg/ml), levofloxacin 0.5% (positive control) and phosphate 
buffer solution (PBS; negative control) in a murine S. aureus ATCC SA29213 bacterial keratitis model (n = 5 
mice/treatment group). (A) Representative slit-lamp images showing the corneal appearance over 3 days 
post-infection in each treatment group. Note the significant infiltrative changes of cornea in the PBS group as 
compared to the CaD23 0.05% and levofloxacin 0.5% groups. (B) Scatter plot showing the bacterial viability of 
S. aureus (in  log10 CFU/ml) after 3 days of treatment. In view of the wide range of results, data is presented as 
median ± interquartile range. (C) Scatter plot showing the ocular clinical scoring of the clinical appearance of the 
S. aureus-infected corneas treated by different treatment. The data is presented as median ± interquartile range. 
The scores are interpreted as follows: 0: Clear cornea or minimal opacity, partially covering the pupil; (b) + 1: 
Mild opacity, partially/fully covering the pupil; (c) + 2: Dense opacity, partially covering the pupil; (d) + 3: Dense 
opacity fully covering the pupil; and (e) + 4: Corneal perforation or phthisis.
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a lower risk of inducing  immunogenicity25,50. Moreover, the antimicrobial efficacy of CaD23 is comparable to 
some of the HDPs that are developed for ocular surface infection, including esculentin-1a (1–21)NH251,  RP44452, 
melimine and its  derivatives40,53, and ε-lysylated Mel-454.
In the time-kill kinetics study, we demonstrated that CaD23 at 2× MIC was able to achieve complete killing 
of S. aureus within 30 min as compared to 4 h with amikacin at 20× MIC (i.e. 8 times slower than CaD23). We 
also observed that increasing the concentration of amikacin from 8× MIC to 20× MIC did not expedite its anti-
bacterial action against S. aureus, suggesting that the speed of bacterial killing is more related to the underlying 
mechanism of action than the concentration of antibiotic. The rapid killing action of CaD23 is likely related to 
a membrane perturbation  effect55, which is in contrast to amikacin where it exerts its anti-bacterial activity via 
intracellular inhibition of the 30S subunit of bacterial  ribosome56. The rapid and membrane disruptive action of 
CaD23 is likely accountable for the low risk of S. aureus developing AMR against CaD23 as the bacteria has less 
time to adapt and require substantial modification of genome to develop effective resistant mechanisms, which 
are shown in conventional antibiotics such as amikacin.
Based on the LDH cytotoxicity assay, CaD23 was shown to be relatively non-cytotoxic (20–30% toxicity) at 
200 μg/ml, with a therapeutic index of > 8–16 against S. aureus (defined by  LC50 concentration divided by MIC 
value). In addition, the hemolytic activity of CaD23 at 200 μg/ml was only less than 10%. Interestingly, the  IC50 
value (based on cell viability assay) was around 50 μg/ml, considerably lower than the  LC50 value. This discrep-
ancy may be due to the fact that some of the cells were metabolically inhibited but the cell membrane was not 
disrupted, therefore the  IC50 value was lower than the  LC50 value. That said, our in vivo corneal epithelial wound 
healing study showed that CaD23 did not demonstrate any significant toxicity when used at 500 μg/ml (or 0.05%), 
which was 10 times higher than the  IC50 value. The observed discrepancy between in vitro and in vivo findings 
is likely attributed to the inherent dynamic environment of ocular surface with eye blinking, high tears turnover, 
and drainage, and dilution of the peptide by the  tears57. This also suggests that in vitro plate-based static assays 
such as cytotoxicity or cell viability assays could potentially overestimate the in vivo cytotoxicity of drugs that 
are developed for ocular topical application. The shortcoming of in vitro assays may be addressed by the recently 
developed novel ex vivo biomimetic model where it could simulate the dynamic and complex interface between 
the ocular surface and the external environment, allowing a better prediction of the in vivo  effect58.
Our in vivo BK study demonstrated that CaD23 0.05% (20× MIC) was able to reduce the bacterial viability of 
S. aureus by 94% when compared to the untreated control group, which was more than the pre-defined endpoint 
of the study (i.e. 1 logCFU or 90% reduction in the bacterial bioburden). However, the effect was not statisti-
cally significant due to the considerably wide standard deviation observed in both the treatment and the control 
groups. This similarly explained the insignificant improvement in the levofloxacin-treated group, though there 
was 1.8 logCFU median reduction in the bacterial bioburden compared to the PBS group. Nevertheless, these 
results serve as a strong proof-of-concept that CaD23 may be employed as a potentially efficacious treatment for 
treating Gram-positive bacterial keratitis, but a larger sample size will be required to fully ascertain its efficacy. In 
addition, we had chosen to sacrifice the mice at day-3 post-infection because S. aureus keratitis had been shown 
to be most severe in C57BL/6J mice at 3-day post-infection, as compared to other stains of mice such as BALB/c 
and A/J mice. In addition, S. aureus keratitis has been shown to improve spontaneously in C57BL/6J mice at 
day-5 post-infection and  beyond59. To investigate the longer-term in vivo antimicrobial efficacy of CaD23 in S. 
aureus keratitis, other strains of mice may be required to examine this aspect.
One potential approach to improve the therapeutic effect of HDP-derived antimicrobial treatment is to 
use them in combination with antibiotics as peptide-antibiotic synergism has been demonstrated in several 
 studies42,43,60. This attractive antimicrobial strategy not only helps extend the lifespan and broaden the antibacte-
rial spectrum of conventional antibiotics, but also reduce the dose-dependent toxicity associated with HDPs and 
 antibiotics61. Recently, our group has also shown that FK16, a cathelicidin-derived molecule, could improve the 
antimicrobial efficacy of vancomycin, a glycopeptide antibiotic, against PA by  eightfold42. This is likely ascribed 
to the different mechanisms of action between FK16 and vancomycin where the membrane disruptive action of 
FK16 facilitates the diffusion of vancomycin across the bacterial membrane. Hence, future work investigating 
the potential synergism between CaD23 and commonly used antibiotics for BK would be useful.
At present, our aim is to develop the human-derived hybrid HDPs as topical treatment for BK. However, it is 
interesting to note that the hemolytic activity of CaD23 was very low (7.1% at 200 μg/ml), suggesting that it can 
potentially be developed for treating systemic infection. It also reduces the concern of systemic toxicity when it 
is applied to the ocular surface because systemic absorption of ocular topical treatment can occur, particularly 
when the drugs are  hydrophobic57. The considerable disparity between the hemolytic activity and cytotoxicity 
against corneal epithelial cells could be attributed to the difference in the membrane structure (particularly the 
cytoskeleton) and the metabolic structures of the non-nucleated cells (e.g. red blood cells) and nucleated cells 
(e.g. corneal epithelial cells)62. Further studies examining the efficacy and stability of CaD23 in serum as well as 
its interaction with blood proteins will be conducted to determine its therapeutic potential for treating systemic 
infection.
In conclusion, we demonstrated that rational hybridization of LL-37 and HBD-2 serves as a useful strategy 
in translating the therapeutic potential of human-derived HDPs. Future work examining the efficacy and safety 
of combined CaD23-antibiotic therapy would be beneficial. Potential strategies such as N- and C-terminal 
modifications, introduction of unnatural amino acids and nanoformulation of CaD23 will be further explored 
with an aim to enhance the antimicrobial efficacy, reduce the toxicity and improve the stability of the  peptide25.
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Materials and methods
The commercially synthesized peptides and commonly used antibiotics for IK were first examined for their 
in vitro antimicrobial efficacy against a range of bacteria. In vitro cytotoxicity of these antimicrobial agents was 
then determined against human corneal epithelial cells (HCE-2, CRL-11135, ATCC, UK) using cell viability assay 
and cytotoxicity assay, and against human erythrocytes using hemolytic assay. The most promising synthetic 
peptide, CaD23, was further examined for its time- and concentration-dependent in vitro antimicrobial activ-
ity. Finally, in vivo efficacy and safety of CaD23 were evaluated in corneal wound healing and S. aureus keratitis 
murine models. All the assays described in this study were conducted in biological duplicate and in at least two 
independent experiments, with appropriate positive controls (PCs) and negative controls (NCs). Continuous 
values were expressed in mean ± standard deviation (SD), unless specified otherwise.
Design and synthesis of HDPs. A template-based design method was used to design our human-derived 
HDPs. The native peptide sequences were obtained from an established protein bank database (https:// www. 
unipr ot. org/). Several human-derived HDPs, specifically HBD-1, -2, and -3, and cathelicidin (LL-37), were sub-
ject to testing and hybridization. The physicochemical properties of the designed peptides, including peptide 
weight, net charge, hydrophobicity (<H>), and amphiphilicity/hydrophobic moment (<μH>, were analyzed 
using a computational programmes such as PepCalc (https:// pepca lc. com/) and HeliQuest (http:// heliq uest. 
ipmc. cnrs. fr). Various strategies, including residue substitution and hybridization, were employed for SAR anal-
ysis and for improving the therapeutic index (i.e. increasing the antimicrobial efficacy and reducing the toxicity 
profile). The native and synthetic peptide sequences are shown in Table 1.
Synthesis of the single and hybrid HDPs was based on the knowledge of the functional regions of the native 
templates. Three single, short-sequenced (truncated) peptides, based on the native template of HBD2, HBD3 
and LL-37, were first generated. Truncated versions of the parent peptides were engineered as this strategy has 
been shown to serve as a useful method in improving the efficacy of peptides and reducing the cost of synthesis, 
which represents a significant translational barrier of peptide-based antimicrobial  therapy25. The C-terminal 
region of HBD2 and HBD3 was synthesised and examined in view of the presence of high cationicity (i.e. rich 
of lysine and/or arginine residues), which are important for the antimicrobial  efficacy26,47,48. In addition, the 
middle region of LL-37, same as the KR12 molecule, was synthesized as it has been shown to exhibit efficacy 
equivalent to the full-length of LL-3746.
All antibiotics, including amikacin (an aminoglycoside) and levofloxacin (a fluoroquinolone), were purchased 
from Sigma-Aldrich, United Kingdom. Both antibiotics were used as positive controls as they were commonly 
used for treating  BK1,4,63. The full-length peptides were commercially produced by Anaspec (Cambridge, UK; for 
LL-37) and PeproTech (London, UK; for HBD-2 and HBD-3). All other peptides were commercially produced 
by Mimotopes (Mulgrave Victoria, Australia) via the traditional solid phase Fmoc synthesis method. All the 
synthetic peptides were purified by reverse-phase high performance liquid chromatography (RP-HPLC) to > 95% 
purity and characterized by mass spectrometry.
Range of microorganisms being tested. A range of Gram-positive and Gram-negative laboratory- and 
clinical-strain bacteria were used for the experiments. These included laboratory-strain methicillin-sensitive S. 
aureus (MSSA; including SH1000 and ATCC SA29213), laboratory-strain MRSA (ATCC MRSA43300), clini-
cal-strain MRSA (MRSA-OS; an IK isolate), laboratory-strain methicillin-sensitive Staphylococcus epidermidis 
(MSSE; ATCC SE12228), laboratory invasive-strain P. aeruginosa (PAO1-L), and clinical cytotoxic-strain P. aer-
uginosa (PA-OS; an IK isolate).
Determination of antimicrobial efficacy using MIC assay. In vitro antimicrobial efficacy of the anti-
biotics and designed HDPs was determined using an established MIC assay with broth microdilution method 
approved by the Clinical and Laboratory Standards Institute (CLSI)64. Briefly, the microorganisms were cultured 
on Tryptone Soya Agar (TSA) and incubated overnight for 18–21 h at 37 °C. Bacterial inoculums were subse-
quently prepared using the direct colony suspension  method64. Three to five bacterial colonies were obtained 
from the agar plate and inoculated into an Eppendorf tube containing 1 ml of cation-adjusted Muller-Hinton 
broth (caMHB), consisting of 20–25 mg/L calcium ions  (Ca2+) and 10–12.5 mg/L magnesium ions  (Mg2+). The 
bacterial suspension was adjusted to achieve a turbidity equivalent to 0.1  OD600 or 0.5 MacFarland, contain-
ing ~ 1.5 ×  108 colony-forming unit (CFU)/ml, which was then further diluted in 1:150 in caMHB to reach a final 
bacterial concentration of ~ 1 ×  106 colony forming units (CFU)/ml. Each treatment (peptide or antibiotic) was 
prepared in 1:2 serial dilution in 96-well polypropylene microplates (with a final treatment volume of 50 μl per 
well), followed by the addition of 50 μl of 1 ×  106 CFU/ml bacteria into each well (with a final bacterial concentra-
tion of 5 ×  105 CFU/ml). As the HDPs are known to be influenced by the salt  content25, the MIC assay was also 
performed in the presence of physiological tear salt concentration (150 mM NaCl). The MIC values, defined as 
the lowest concentration of the antimicrobial agent that prevented any visible growth of bacteria, were deter-
mined after 24 h of incubation with treatment.
Cell viability and cytotoxicity assays. Cell viability and cytotoxicity of antibiotics and peptides were 
determined against human corneal epithelial cells (HCE-2, CRL-11135, ATCC, Manassas, Virginia, USA) using 
cell-counting-kit-8 (CCK-8) assay (Sigma Aldrich, Merck Life Science UK Limited, Dorset, UK) and lactate 
dehydrogenase (LDH) assay (ThermoFisher Scientific, UK), respectively, as per manufacturer’s guidelines. 
HCE-2 cells were cultured and seeded into a 96-well plate at a density of 7.5 ×  103 cells/well and allowed to 
attach overnight and grew to 80–90% confluency in keratinocyte serum free medium (KSFM) supplemented 
with human recombinant epidermal growth factor, bovine pituitary extract, hydrocortisone, and insulin. Once 
11
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18304  | https://doi.org/10.1038/s41598-021-97821-3
www.nature.com/scientificreports/
the confluency reached 80–90%, the cells were incubated with treatment for 3 h before  OD450 measurement was 
taken using BMG Clariostar microplate reader (BMG Labtech Ltd., Aylesbury, UK). Appropriate controls were 
used, including 0.1% Triton X-100 as positive control and KSFM as negative control. Cell viability was calculated 
using the following formula: [((Itreatment –  INC)/(INC)) × 100; I = intensity] and cytotoxicity was calculated using the 
following formula: [((Itreatment –  INC)/(IPC –  INC)) × 100].
Hemolytic assay. Ethical approval was obtained from the Local Research Ethics Committee of University 
of Nottingham prior to the experiment (Ref: 176-1812). The experiment was conducted in accordance with the 
relevant guidelines and regulations. Hemolytic assay was performed according to the previously established 
 protocol42. Briefly, 5 ml of fresh human blood was collected from healthy participants with written informed 
consent, in an EDTA tube and centrifuged for 10 min at 1300g at 10 °C for separation of plasma. The remaining 
erythrocytes were rinsed and centrifuged further three times in  Ca2+/Mg2+ free Dulbecco’s phosphate-buffered 
saline (DPBS). Subsequently, erythrocytes were diluted to 8% v/v in DPBS and incubated with 100 μl of treat-
ment, positive control (1% Triton X-100) and negative control (DPBS), all in 1:1 ratio, for 1 h (final erythrocytes 
concentration = 4% v/v). After 1 h of incubation, the plate was centrifuged at 500×g for 5 min and 100 μl of 
supernatant of each well was transferred into a 96-well plate for measurement at  OD540. Hemolysis (%) was cal-
culated as [(Itreatment –  INC)/(IPC –  INC)] × 100.
Time‑kill kinetics assay. Time-kill kinetics assay was performed to determine the time-dependent and 
concentration-dependent in vitro antimicrobial effects of the CaD23 and amikacin, a commonly used topical 
antibiotics for BK, against 100 μl of ~ 1 ×  106 CFU/ml of SH1000 (1:1 treatment-bacteria ratio) at various time 
points, including 0 min (pre-treatment), 15 min, 30 min, 60 min, 2 h, 4 h, and 24 h. At each time point, 10 μl 
of the treated bacteria was transferred to an Eppendorf tube containing 90 μl of PBS, which was then serially 
diluted in 1:10 concentration for inoculation on agar plates and incubated overnight for 18–21 h at 37 °C for 
enumeration of CFU.
Multipassage antimicrobial resistance (AMR) study. Multipassage AMR assays were performed to 
evaluate the risk of development of AMR of S. aureus (ATCC SA29213) against CaD23 and amikacin over 10 
consecutive passages (days). The assay was conducted in a similar manner of the MIC assay described above. 
After determining the initial MIC level of each treatment at baseline (passage 1), bacterial suspensions were 
obtained from the 0.5× MIC well of each treatment and were adjusted in caMHB to achieve a turbidity equiva-
lent to 0.1  OD600 (containing ~ 1.5 ×  108 CFU/ml). This was then further diluted in 1:150 in caMHB to reach a 
final bacterial concentration of ~ 1 ×  106 colony forming units (CFU)/ml. Subsequently, 50 μl of 1 ×  106 CFU/ml 
of the bacteria was added to the corresponding serially diluted treatment and the MIC level was determined after 
24 h of incubation with treatment. Development of AMR was defined as ≥ fourfold increase in the MIC level 
compared to the baseline.
In vivo efficacy and safety studies. The in vivo studies were conducted in two stages, namely the cor-
neal wound healing study (for safety) and BK study (for efficacy), based on previously established  protocols54,65. 
Wild-type C57BL/6J mice (8–9 weeks old, male, average weight of 25 g) were used in view of the consistent and 
reproducible results demonstrated in previous  studies54,65. The mice were maintained and treated in compli-
ance with the Guide for the Care and Use of Laboratory Animals (National Research Council) and the ARVO 
statement for the Use of Animals in Ophthalmic and Vision Research. All animal studies were conducted at 
the Singapore Eye Research Institute, Singapore, and were approved by the Animal Welfare & Ethical Review 
Body (AWERB), University of Nottingham, UK (Ref: UoN-Non-UK #16), the Institutional Animal Care and 
Use Committee (IACUC) and the Institutional Biosafety Committee (IBC) of SingHealth, Singapore (Ref: 2019/
SHS/1491). All experiments were performed in accordance with relevant guidelines and regulations. General 
anesthesia was administered using intraperitoneal injections of xylazine (10 mg/kg) and ketamine (80 mg/kg)], 
and a drop of topical proxymetacaine hydrochloride 0.5% was administered immediately before wounding and/
or infecting the corneas. Upon completion of the experiments, all mice were sacrificed according to the method 
of humane killing set out in Animals (Scientific Procedures) Act 1986 Schedule 1 using overdose of general 
anesthesia via intraperitoneal route. The study was reported in accordance with ARRIVE guidelines (https:// 
arriv eguid elines. org)66.
In vivo corneal wound healing study. Drug drainage, blinking and tear film were considered during 
dosing translation from in vitro to in vivo  use52. Based on the MIC of CaD23 against S. aureus ATCC 29213 
(= 25 μg/ml), a range of concentration of CaD23 was chosen, including 300 μg/ml (0.03%; 12× MIC), 500 μg/ml 
(0.05%; 20× MIC) and 1 mg/ml (0.1%; 40× MIC).
In vivo safety of CaD23 (in 0.03%, 0.05% or 0.1%), and PBS (negative control) was first determined in a mouse 
corneal epithelial wound healing model. In the absence of in vivo pilot data of our designed HDPs, the sample 
size was calculated based on a previous  study67. This was designed as a non-inferiority trial to ensure that the 
HDPs did not affect the wound healing when compared to PBS (control). The non-inferiority margin was set at 
10% difference of the wound size between HDPs and PBS at 3 days (deemed as significantly different), with a 
standard deviation (SD) of 5% (Cohen’s d = 2.0), power = 80% and p < 0.05. A minimum sample size of 4 mice/
treatment group was needed.
All mice were randomly allocated to each of the four treatment groups (n = 4 mice/group). Prior to the study, 
all eyes were examined with slit-lamp biomicroscopy to confirm the health of corneas. Under general and topical 
anesthesia, the central 2 mm corneal epithelium was gently debrided with sterile Beaver mini-blades, leaving the 
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basal lamina intact. Each treatment was applied immediately after wounding, then 4 times a day at 3-h interval 
for 3 days (total dose of treatment per mouse = 14). Corneal epithelial defect was assessed using a cobalt-blue 
filter-equipped slit-lamp biomicroscopy and photography with staining with topical sodium fluorescein 1% at 
baseline (immediately post-debridement) and daily up to 3 days post-treatment. Fluorescein-stained images of 
the corneal wound defect were analyzed using ImageJ software (https:// imagej. nih. gov/ ij/)68. The main outcome 
measure was the wound size at the end of day 1, 2 and 3 [expressed as % of the original wound size in mean and 
standard deviation (SD)]. Difference in the wound size between groups was analyzed using one-way ANOVA 
with Dunnett’s post hoc test (PBS as the control group).
In vivo S. aureus keratitis study. Based on the in vivo safety data, the highest tolerable concentration of 
CaD23, 500 μg/ml (0.05%), was used in the subsequent S. aureus keratitis murine model. Levofloxacin 0.5%, a 
commonly used antibiotic for BK in clinical  setting4, and PBS were used as the positive and negative controls, 
respectively. In the absence of in vivo pilot data, the sample size was calculated based on a previous  study65. To 
detect an effect size of 1 LogCFU (or 10 times) difference in the bacterial load (significant antimicrobial efficacy) 
between HDPs (mean = 5 logCFU) and PBS (mean = 6 logCFU; NC), with a SD of 0.5 logCFU (Cohen’s d = 2.0), 
power = 80% and p < 0.05, a minimum sample size of 4–5 mice/group is required.
All mice were randomly allocated to each treatment group (n = 5 mice/group). Slit-lamp examination was 
performed before the start of experiment to confirm the health of corneas. Under general and topical anesthesia, 
the central 2 mm corneal epithelium was gently removed with sterile Beaver mini-blades. 10 μl of ~ 1 ×  108 CFU/
ml of ATCC SA29213 was applied topically onto the cornea and the lid was held shut for 1 min. At 6 h post-
infection, 10 μl of treatment was applied directly onto the infected corneas with a dose regimen of 4 times a day 
at 3-h interval for 3 days (total dose of treatment per mouse = 12). The eyes were monitored daily using slit-lamp 
biomicroscopy and photography. Ocular clinical scoring was adapted from a previous method described by 
Clemens et al.52 with minor modifications: (a) 0: Clear cornea or minimal opacity, partially covering the pupil; 
(b) + 1: Mild opacity, partially/fully covering the pupil; (c) + 2: Dense opacity, partially covering the pupil; (d) + 3: 
Dense opacity fully covering the pupil; and (e) + 4: Corneal perforation or phthisis.
At the end of day 3, all animals were sacrificed, and the infected eyes were enucleated. The whole corneas 
were subsequently dissected and homogenized in 1 ml of sterile PBS using sterile glass micro-beads. The homog-
enised infected corneal tissue suspension was serially diluted in 1:10 and plated on TSA plates in triplicates for 
enumeration of CFU after 24 h incubation at 37 °C. The main outcome measures were the ocular clinical scoring 
and the residual bacterial load at 3-day post-treatment (expressed as  log10 CFU/ml, which was the same as  log10 
CFU/cornea) and the difference among groups was analyzed using one-way ANOVA with Dunnett’s post hoc 
test (PBS as the control group).
Received: 3 June 2021; Accepted: 24 August 2021
References
 1. Ting, D. S. J., Ho, C. S., Deshmukh, R., Said, D. G. & Dua, H. S. Infectious keratitis: an update on epidemiology, causative micro-
organisms, risk factors, and antimicrobial resistance. Eye 35(4), 1084–1101 (2021).
 2. Ung, L., Bispo, P. J. M., Shanbhag, S. S., Gilmore, M. S. & Chodosh, J. The persistent dilemma of microbial keratitis: Global burden, 
diagnosis, and antimicrobial resistance. Surv. Ophthalmol. 64(3), 255–271 (2019).
 3. Tan, S. Z. et al. Twelve-year analysis of microbial keratitis trends at a UK tertiary hospital. Eye 31(8), 1229–1236 (2017).
 4. Ting, D. S. J. et al. 12-year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious 
keratitis: The Nottingham Infectious Keratitis Study. Br. J. Ophthalmol. 105(3), 328–333 (2021).
 5. Asbell, P. A., Sanfilippo, C. M., Sahm, D. F. & DeCory, H. H. Trends in antibiotic resistance among ocular microorganisms in the 
United States from 2009 to 2018. JAMA Ophthalmol. 138(5), 439–450 (2020).
 6. Ting, D. S. J., Settle, C., Morgan, S. J., Baylis, O. & Ghosh, S. A 10-year analysis of microbiological profiles of microbial keratitis: 
The North East England Study. Eye 32(8), 1416–1417 (2018).
 7. Lee, J. W., Somerville, T., Kaye, S. B. & Romano, V. Staphylococcus aureus keratitis: Incidence, pathophysiology, risk factors and 
novel strategies for treatment. J. Clin. Med. 10(4), 758 (2021).
 8. Ting, D. S. J., Henein, C., Said, D. G. & Dua, H. S. Photoactivated chromophore for infectious keratitis-corneal cross-linking 
(PACK-CXL): A systematic review and meta-analysis. Ocul. Surf. 17(4), 624–634 (2019).
 9. Tabatabaei, S. A. et al. A randomized clinical trial to evaluate the usefulness of amniotic membrane transplantation in bacterial 
keratitis healing. Ocul. Surf. 15(2), 218–226 (2017).
 10. Ting, D. S. J., Henein, C., Said, D. G. & Dua, H. S. Amniotic membrane transplantation for infectious keratitis: A systematic review 
and meta-analysis. Sci. Rep. 11(1), 13007 (2021).
 11. Khor, W. B. et al. The Asia Cornea Society infectious keratitis study: A prospective multicenter study of infectious keratitis in Asia. 
Am. J. Ophthalmol. 195, 161–170 (2018).
 12. Ting, D. S. J. et al. Polymicrobial keratitis with Cryptococcus curvatus, Candida parapsilosis, and Stenotrophomonas maltophilia 
after penetrating keratoplasty: A rare case report with literature review. Eye Contact Lens. 45(2), e5–e10 (2019).
 13. Khoo, P., Cabrera-Aguas, M. P., Nguyen, V., Lahra, M. M. & Watson, S. L. Microbial keratitis in Sydney, Australia: Risk factors, 
patient outcomes, and seasonal variation. Graefes Arch. Clin. Exp. Ophthalmol. 258(8), 1745–1755 (2020).
 14. Asbell, P. A. et al. Antibiotic resistance among ocular pathogens in the United States: Five-year results from the antibiotic resistance 
monitoring in ocular microorganisms (ARMOR) surveillance study. JAMA Ophthalmol. 133(12), 1445–1454 (2015).
 15. Nithya, V., Rathinam, S., Siva Ganesa Karthikeyan, R. & Lalitha, P. A ten year study of prevalence, antimicrobial susceptibility 
pattern, and genotypic characterization of Methicillin resistant Staphylococcus aureus causing ocular infections in a tertiary eye 
care hospital in South India. Infect. Genet. Evol. 69, 203–210 (2019).
 16. Kaye, S. et al. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis. Investig. Ophthalmol. Vis. 
Sci. 51(1), 362–368 (2010).
 17. Lalitha, P. et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin. Infect. 
Dis. 54(10), 1381–1387 (2012).
13
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18304  | https://doi.org/10.1038/s41598-021-97821-3
www.nature.com/scientificreports/
 18. Ting, D. S. J. et al. Arthrographis kalrae keratitis complicated by endophthalmitis: A case report with literature review. Eye Contact 
Lens. 46(6), e59–e65 (2020).
 19. Ting, D. S. J. et al. Risk Factors, clinical outcomes and prognostic factors of bacterial keratitis: The Nottingham infectious keratitis 
study. Front. Med. 8, 715118 (2021).
 20. Hutchings, M. I., Truman, A. W. & Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 51, 72–80 (2019).
 21. Hancock, R. E. & Lehrer, R. Cationic peptides: A new source of antibiotics. Trends Biotechnol. 16(2), 82–88 (1998).
 22. Mookherjee, N., Anderson, M. A., Haagsman, H. P. & Davidson, D. J. Antimicrobial host defence peptides: Functions and clinical 
potential. Nat. Rev. Drug Discov. 19, 311–332 (2020).
 23. Mohammed, I., Said, D. G. & Dua, H. S. Human antimicrobial peptides in ocular surface defense. Prog. Retin. Eye Res. 61, 1–22 
(2017).
 24. Kolar, S. S. & McDermott, A. M. Role of host-defence peptides in eye diseases. Cell Mol. Life Sci. 68(13), 2201–2213 (2011).
 25. Ting, D. S. J., Beuerman, R. W., Dua, H. S., Lakshminarayanan, R. & Mohammed, I. Strategies in translating the therapeutic 
potentials of host defense peptides. Front. Immunol. 11, 983 (2020).
 26. Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 
24(12), 1551–1557 (2006).
 27. McIntosh, R. S. et al. The spectrum of antimicrobial peptide expression at the ocular surface. Investig. Ophthalmol. Vis. Sci. 46(4), 
1379–1385 (2005).
 28. Haynes, R. J., Tighe, P. J. & Dua, H. S. Innate defence of the eye by antimicrobial defensin peptides. Lancet 352(9126), 451–452 
(1998).
 29. Haynes, R. J., Tighe, P. J. & Dua, H. S. Antimicrobial defensin peptides of the human ocular surface. Br. J. Ophthalmol. 83(6), 
737–741 (1999).
 30. Mohammed, I. et al. Antimicrobial peptides in human corneal tissue of patients with fungal keratitis. Br. J. Ophthalmol. 105(8), 
1172–1177 (2021).
 31. Otri, A. M. et al. Antimicrobial peptides expression by ocular surface cells in response to Acanthamoeba castellanii: An in vitro 
study. Br. J. Ophthalmol. 94(11), 1523–1527 (2010).
 32. Abedin, A., Mohammed, I., Hopkinson, A. & Dua, H. S. A novel antimicrobial peptide on the ocular surface shows decreased 
expression in inflammation and infection. Investig. Ophthalmol. Vis. Sci. 49(1), 28–33 (2008).
 33. Otri, A. M. et al. Variable expression of human beta defensins 3 and 9 at the human ocular surface in infectious keratitis. Investig. 
Ophthalmol. Vis. Sci. 53(2), 757–761 (2012).
 34. Huang, L. C., Jean, D., Proske, R. J., Reins, R. Y. & McDermott, A. M. Ocular surface expression and in vitro activity of antimicrobial 
peptides. Curr. Eye Res. 32(7–8), 595–609 (2007).
 35. Gordon, Y. J. et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent 
antibacterial and antiviral activity. Curr. Eye Res. 30(5), 385–394 (2005).
 36. Li, J. et al. Membrane active antimicrobial peptides: translating mechanistic insights to design. Front. Neurosci. 11, 73 (2017).
 37. Fjell, C. D., Hiss, J. A., Hancock, R. E. & Schneider, G. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug 
Discov. 11(1), 37–51 (2011).
 38. Boman, H. G., Wade, D., Boman, I. A., Wahlin, B. & Merrifield, R. B. Antibacterial and antimalarial properties of peptides that 
are cecropin-melittin hybrids. FEBS Lett. 259(1), 103–106 (1989).
 39. Wei, X. B. et al. Novel hybrid peptide cecropin A (1-8)-LL37 (17-30) with potential antibacterial activity. Int. J. Mol. Sci. 17(7), 983 
(2016).
 40. Willcox, M. D., Hume, E. B., Aliwarga, Y., Kumar, N. & Cole, N. A novel cationic-peptide coating for the prevention of microbial 
colonization on contact lenses. J. Appl. Microbiol. 105(6), 1817–1825 (2008).
 41. Willcox, M. D. et al. The development of an antimicrobial contact lens—From the laboratory to the clinic. Curr. Protein Pept. Sci. 
21(4), 357–368 (2020).
 42. Mohammed, I., Said, D. G., Nubile, M., Mastropasqua, L. & Dua, H. S. Cathelicidin-derived synthetic peptide improves therapeutic 
potential of vancomycin against Pseudomonas aeruginosa. Front. Microbiol. 10, 2190 (2019).
 43. Kampshoff, F., Willcox, M. D. P. & Dutta, D. A pilot study of the synergy between two antimicrobial peptides and two common 
antibiotics. Antibiotics 8(2), 60 (2019).
 44. Saugar, J. M. et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter bau-
mannii: Molecular basis for the differential mechanisms of action. Antimicrob. Agents Chemother. 50(4), 1251–1256 (2006).
 45. McDermott, A. M. The role of antimicrobial peptides at the ocular surface. Ophthalmic Res. 41(2), 60–75 (2009).
 46. Wang, G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. 
Biol. Chem. 283(47), 32637–32643 (2008).
 47. Krishnakumari, V. & Nagaraj, R. Binding of peptides corresponding to the carboxy-terminal region of human-β-defensins-1-3 
with model membranes investigated by isothermal titration calorimetry. Biochim. Biophys. Acta. 1818(5), 1386–1394 (2012).
 48. Dhople, V., Krukemeyer, A. & Ramamoorthy, A. The human beta-defensin-3, an antibacterial peptide with multiple biological 
functions. Biochim. Biophys. Acta. 1758(9), 1499–1512 (2006).
 49. Strahl, H. & Errington, J. Bacterial membranes: Structure, domains, and function. Annu. Rev. Microbiol. 71, 519–538 (2017).
 50. Mahlapuu, M., Hakansson, J., Ringstad, L. & Bjorn, C. Antimicrobial peptides: An emerging category of therapeutic agents. Front. 
Cell Infect. Microbiol. 6, 194 (2016).
 51. Kolar, S. S. N. et al. Esculentin-1a(1–21)NH2: A frog skin-derived peptide for microbial keratitis. Cell Mol. Life Sci. 72(3), 617–627 
(2015).
 52. Clemens, L. E. et al. Designed host defense peptides for the treatment of bacterial keratitis. Investig. Ophthalmol. Vis. Sci. 58(14), 
6273–6281 (2017).
 53. Dutta, D., Zhao, T., Cheah, K. B., Holmlund, L. & Willcox, M. D. P. Activity of a melimine derived peptide Mel4 against Steno-
trophomonas, Delftia, Elizabethkingia, Burkholderia and biocompatibility as a contact lens coating. Cont. Lens Anterior Eye. 40(3), 
175–183 (2017).
 54. Mayandi, V. et al. Rational substitution of ε-lysine for α-Lysine enhances the cell and membrane selectivity of pore-forming melit-
tin. J. Med. Chem. 63(7), 3522–3537 (2020).
 55. Ting, D. S. J. et al. Evaluation of host defense peptide (CaD23)-Antibiotic interaction and mechanism of action: Insights from 
experimental and molecular dynamics simulations studies. bioRxiv https:// doi. org/ 10. 1101/ 2021. 06. 26. 450050 (2021).
 56. Kapoor, G., Saigal, S. & Elongavan, A. Action and resistance mechanisms of antibiotics: A guide for clinicians. J. Anaesthesiol. Clin. 
Pharmacol. 33(3), 300–305 (2017).
 57. Farkouh, A., Frigo, P. & Czejka, M. Systemic side effects of eye drops: A pharmacokinetic perspective. Clin. Ophthalmol. 10, 
2433–2441 (2016).
 58. Seo, J. et al. Multiscale reverse engineering of the human ocular surface. Nat. Med. 25(8), 1310–1318 (2019).
 59. Girgis, D. O., Sloop, G. D., Reed, J. M. & O’Callaghan, R. J. A new topical model of Staphylococcus corneal infection in the mouse. 
Investig. Ophthalmol. Vis. Sci. 44(4), 1591–1597 (2003).
 60. Lakshminarayanan, R. et al. Branched peptide, B2088, disrupts the supramolecular organization of lipopolysaccharides and sen-
sitizes the Gram-negative bacteria. Sci. Rep. 6, 25905 (2016).
14
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18304  | https://doi.org/10.1038/s41598-021-97821-3
www.nature.com/scientificreports/
 61. Mishra, B., Reiling, S., Zarena, D. & Wang, G. Host defense antimicrobial peptides as antibiotics: Design and application strategies. 
Curr. Opin. Chem. Biol. 38, 87–96 (2017).
 62. Smith, J. E. Erythrocyte membrane: Structure, function, and pathophysiology. Vet. Pathol. 24(6), 471–476 (1987).
 63. Tavassoli, S. et al. An 11-year analysis of microbial keratitis in the South West of England using brain-heart infusion broth. Eye 
33(10), 1619–1625 (2019).
 64. Clinical & Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bactera that Grow 
Aerobically, 11th ed (2019).
 65. Lin, S. et al. Symmetrically substituted xanthone amphiphiles combat gram-positive bacterial resistance with enhanced membrane 
selectivity. J. Med. Chem. 60(4), 1362–1378 (2017).
 66. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE 
guidelines for reporting animal research. PLoS Biol. 8(6), e1000412 (2010).
 67. Aung, T. T. et al. Biofilms of pathogenic nontuberculous mycobacteria targeted by new therapeutic approaches. Antimicrob Agents 
Chemother. 60(1), 24–35 (2016).
 68. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9(7), 671–675 
(2012).
Author contributions
Study design and conceptualisation: D.S.J.T., R.W.B., R.L., I.M., H.S.D. Data collection: D.S.J.T., E.T.L.G., V.M., 
J.M.F.B., T.T.A., M.H.P. Data analysis and interpretation: D.S.J.T., M.N., L.M., D.G.S., H.M.H., V.A.B., R.W.B., 
R.L., I.M., H.S.D. Manuscript drafting: D.S.J.T. Critical review/revision of the manuscript: E.T.L.G., V.M., J.M.F.B., 
T.T.A., M.H.P., M.N., L.M., D.G.S., H.M.H., V.A.B., R.W.B., R.L., I.M., H.S.D. Final approval of the manuscript: 
All authors. Funding acquisition: D.S.J.T.
Funding
D.S.J.T. is supported by the Medical Research Council/Fight for Sight (FFS) Clinical Research Fellowship (MR/
T001674/1), the FFS/John Lee, Royal College of Ophthalmologists Primer Fellowship (24CO4), and the Univer-
sity of Nottingham International Research Collaboration Fund (A2RRG1). I.M. acknowledges funding support 
from the Medical Research Council–Confidence in Concept Scheme (MRC-CIC_2019-028).
Competing interests 
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to H.S.D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
